<DOC>
	<DOCNO>NCT02002390</DOCNO>
	<brief_summary>Stroke one main severe disease public health importance . Increasing evidence suggest inflammatory mechanism play significant role stroke . So , immune target suppose effective one . The sphingosine-1-phosphate receptor regulator Fingolimod ( FTY720 ) effective immunology modulator widely use autoimmune disease testify effective stoke animal model .</brief_summary>
	<brief_title>Efficacy Safety FTY720 Acute Stroke</brief_title>
	<detailed_description>This study enroll 87 stroke patient diagnose stroke meet inclusion criterion . After successfully meet initial screening criterion , investigator contact family , explain study , send consent form review . After , patient give 0.5mg/day oral fingolimod course 3 consecutive day , investigator make neurofunctional assessment 7days , 30 day 90days oral fingolimod . And Magnetic Resonance brain , 7days , 14days 90days oral fingolimod . Furthermore 5ml intravenous blood flow cytometry also take 1day,3days,7days fingolimod use .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Age 1880 year Clinical presentation spontaneous intracerebral hemorrhage/ischemic stroke MRI/MRA scan compatible spontaneous intracerebral hemorrhage/ ischemic stroke Time fty720 treatment &lt; 72 h symptom onset Glasgow Coma Score &gt; 6 initial presentation improvement Glasgow Coma Score &gt; 6 within time frame enrollment . Primary supratentorial ICH â‰¥5cc &lt; 30cc TOAST : Largeartery atherosclerosis Patients undergo surgical evacuation intracerebral hemorrhage Inability undergo neuroimaging Magnetic Resonance Glasgow Coma Score &lt; 6 . Baseline modify Rankin Scale score &gt; 1 Primary intraventricular hemorrhage ICH due coagulopathy ( PT &gt; 15 International Normalized Ratio &gt; 1.3 , Partial Thromboplastin Time &gt; 36 ) trauma Thrombocytopenia : platelet count &lt; 100 000 Clinically significant hepatic disease demonstrate history , clinical exam ( ascites , varix ) , laboratory finding ( LFTs &gt; 2x normal , coagulopathy describe ) Comorbid condition likely complicate therapy include limited following : history New York Heart Association class II , III , IV Congestive Heart Failure ; endstage acquire immune deficiency syndrome Pregnancy Malignancy ( history active ) Bradyarrhythmia Atrioventricular Block Concomitant use antineoplastic , immunosuppressive immune modulate therapy Macular Edema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Stroke , Fingolimod ( FTY 720 ) , treatment</keyword>
</DOC>